CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Open-market sale President & CIO sold 335,174 shares at an average $36.88 ($12,360,813)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale President & CIO sold 664,826 shares at an average $36.34 ($24,160,402)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $34.95 ($6,990,000)
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 144 Insider Sale of Securities
- 4 Grant or award Director acquired 405 shares (grant or award)
- 4 Grant or award Director acquired 543 shares (grant or award)
- 4 Grant or award Director acquired 775 shares (grant or award)
- 4 Shares withheld for taxes CEO gave up 76,171 shares (to pay taxes)
Page 4 of 51 · 1,008 filings